Study protocol

A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device with a 20G EUS ProCore Fine Needle Biopsy (FNB) Device

ASPRO trial (ASPiration versus PROcore)

ProCore study group

PROTOCOL TITLE

Protocol ID	ASPRO trial
Short title	Comparing a 25G EUS-FNA with a 20G EUS ProCore
	FNB Device
Version	Version I
Date	13-10-2014
Coordinating investigator	Drs P.A. van Riet
	Department of Gastroenterology & Hepatology,
	Room Ca-415, Erasmus University Medical Center,
	Rotterdam, the Netherlands
	Email; p.vanriet@erasmusmc.nl
Principal investigator	Dr D.L. Cahen
	Department of Gastroenterology & Hepatology,
(See paragraph 3.1 for a list of all	Room H-337, Erasmus University Medical Center,
principal investigators per site)	Rotterdam, the Netherlands
	Email; djuna@cahen.nl
Sponsor	SLO (in Dutch: Stichting Lever Onderzoek, in English:
	Foundation for Liver and Gastrointestinal Research)
	on behalf of the Department of Gastroenterology and
	Hepatology of the Erasmus University Medical Center in
	Rotterdam, the Netherlands
Subsidising party of	Cook Medical
unrestricted grant	O'Halloran Road
	National Technology Park
	Limerick, Ireland
	www.cookmedical.com
Independent physician	Dr D. Sprengers
	Department of Gastroenterology & Hepatology, Erasmu
	University Medical Center, Rotterdam, the Netherlands

Laboratory sites	Department of Clinical Pathology, Erasmus University
	Medical Center, Rotterdam, the Netherlands
Pharmacy	Not applicable

SUMMARY

Rationale: During Endoscopic Ultrasound (EUS), tissue samples can be obtained with different techniques. Fine needle aspiration (FNA) provides a cytological specimen. With fine needle biopsy (FNB), a histological specimen is obtained, which generally results in a better diagnostic performance. However, FNB needles are stiffer and more difficult to handle, and can therefore result in less tissue acquisition.

Objectives: To compare the performance and diagnostic accuracy of two EUS-guided tissue acquisition devices; a 25G Echotip Ultra Fine Needle Aspiration (FNA) device and a new, more flexible 20G Echotip ProCore Fine Needle Biopsy (FNB) device.

Study design: International randomized multicenter trial.

Study population: Patients ≥18 years old, referred for EUS-guided tissue sampling of a: (I) pancreatic mass lesion, (II) lymph node, or (III) other submucosal or undefined mass (non-pancreatic), ≥ I cm in size.

Intervention: EUS-guided tissue acquisition by means of either the 25G Echotip Ultra FNA device, or the 20G Echotip ProCore FNB device.

Main study parameters/endpoints: The main endpoint is the diagnostic performance, measured against the *gold standard* diagnosis (based on the surgical resection specimen or in non-operated patients, the outcome of the diagnostic work-up (i.e. tissue sampling and imaging studies), confirmed by a compatible clinical disease course). Secondary endpoints include I. technical success, II, specimen specifics, such as; quality, presence of tissue cores, and pathological classification (cytology, cell-block, or histology), III. procedural aspects, such as; safety, the yield of a single needle pass, and the value of on-site pathological evaluation, and IV. inter-observer variation.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There are no additional risks involved. Patients are referred for EUS-guided tissue acquisition, as part of the standard diagnostic work-up. Previous reports showed EUS-guided FNA and FNB sampling to be equally safe.